Changing the Ovarian Cancer Treatment Landscape with a DNA-Mediated Immunotherapy
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Changing the Ovarian Cancer Treatment Landscape with a DNA-Mediated Immunotherapy
-
Narrated by:
-
By:
About this listen
Ovarian cancer remains one of the deadliest cancers affecting women, and it is expected to claim nearly 13,000 lives in the United States in 2025. Despite progress in survival rates, nearly 80 percent of patients are still diagnosed at advanced stages, when the disease has already spread and is difficult to treat. Imunon’s experimental DNA-mediated immunotherapy is designed to deliver interleukin-12 directly into the tumor. A phase 2 study demonstrated that the experimental therapy, when combined with the standard of care, provided a 13-month survival benefit compared to women receiving only the standard of care. We spoke to Stacy Lindborg, CEO of Imunon, about the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease.